LifeTech Scientific Corporation
LFTSF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | -1.21 | 0.02 | -0.49 |
| FCF Yield | 5.09% | 1.57% | -1.04% | 1.37% |
| EV / EBITDA | 91.59 | 84.61 | 32.88 | 48.29 |
| Quality | ||||
| ROIC | 0.78% | -0.69% | 4.39% | 4.24% |
| Gross Margin | 73.56% | 71.60% | 78.95% | 78.20% |
| Cash Conversion Ratio | 7.10 | -33.34 | 0.50 | 4.52 |
| Growth | ||||
| Revenue 3-Year CAGR | 21.23% | 25.16% | 25.30% | 24.49% |
| Free Cash Flow Growth | 215.93% | 248.99% | -183.82% | -24.21% |
| Safety | ||||
| Net Debt / EBITDA | -10.99 | -8.22 | -3.49 | -7.97 |
| Interest Coverage | 0.00 | -8.29 | 0.00 | -4,798.54 |
| Efficiency | ||||
| Inventory Turnover | 0.36 | 0.35 | 0.25 | 0.28 |
| Cash Conversion Cycle | -142.11 | 251.77 | 80.31 | 251.54 |